Vitrolife and GE Healthcare partner to improve assisted reproductive technology offerings

Report this content

In the lead up to the European Society of Human Reproduction and Embryology (ESHRE) annual conference, GE Healthcare and Vitrolife are partnering to improve patient outcomes in assisted reproductive medicine.

More than 20 years ago, Vitrolife was a key player in introducing the technique and needles for ultrasound-guided oocyte retrieval - now a standard practice in IVF. Vitrolife’s needles feature new echomarking to maximize ultrasound visibility, and an even sharper tip to enable a smooth penetration of the tissue. GE Healthcare’s Voluson™ ultrasound systems enable physicians to monitor stimulated follicles, determine the optimal time for oocyte retrieval, and follow these needles in great detail throughout retrieval.

“With the rise of IVF treatments, we’re committed to providing the highest-quality technology to clinicians, and improving the patient’s experience at every step,” said Roland Rott, General Manager of Women’s Health Ultrasound, GE Healthcare. “We are thrilled to partner with Vitrolife to connect the patient journey in and out of the IVF clinic to ensure the best possible result for the patient.”

From the early diagnosis of potential challenges and evaluating the causes of infertility to monitoring the transfer and ensuring a healthy pregnancy, GE Healthcare’s ultrasound technologies play a key role in reproductive medicine. Similarly, Vitrolife’s assisted reproductive technology offerings incorporate the complete IVF process from the oocyte retrieval through fertilization, embryo culturing, and transfer.

“This partnership supports Vitrolife’s ambition to offer IVF clinics the most effective products in its efforts to assist patients’ desire to have children” said Thomas Axelsson, CEO of Vitrolife AB. “We look forward to partnering with GE Healthcare on joint educational activities for IVF clinics around key procedures and the potential to collaborate on future development projects.”

About GE Healthcare
GE Healthcare is the $19 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services. With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps improve outcomes more efficiently for patients, healthcare providers, researchers and life sciences companies around the world.

June 28, 2018
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 10.00 am CET on June 28, 2018.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 370 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: Website:



Documents & Links